← 返回

一种用于个体化自体 T 细胞采集以制备 CAR-T 细胞的新型预测算法

英文原题:A novel predictive algorithm to personalize autologous T-cell harvest for chimeric antigen receptor T-cell manufacture.

查看英文原题

A novel predictive algorithm to personalize autologous T-cell harvest for chimeric antigen receptor T-cell manufacture.

PubMed 2022/12/11(内容时间) Cytotherapy Q1 · IF 4.5(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

作者提出了一种可迁移的模型,该模型纳入了采集前可获取的临床和实验室变量,适用于 T 细胞治疗领域。在进一步验证之前,该模型可用于制定个体化白细胞采集计划,并简化细胞采集流程——这是业内公认的瓶颈。

研究思路结论见上方概要

目前最广泛接受的CAR-T 细胞制备起始材料是通过白细胞分离术(也称为T细胞采集)获得的自体CD3+ T细胞。随着这种治疗模式的发展势头增强,而单采单位难以满足采集名额的需求,简化这一关键步骤的策略势在必行。

这项对262份T细胞采集物的回顾性分析,以健康供者作为对照队列,分析了影响B细胞恶性肿瘤成人患者CD3+ T细胞产量的参数。总体目标是设计一种新的预测算法,以指导单采机上所需处理血量(PBV)(L),从而达到特定的CD3+目标产量。

多因素分析中与CD3+ T细胞产量相关的因素包括外周血CD3+计数(自然对数,10 9 /L)、血细胞比容(HCT)和PBV,其系数分别为0.86(95%置信区间[CI],0.80-0.92,P < 0.001)、1.30(95% CI,0.51-2.08,P = 0.001)和0.09(95% CI,0.07-0.11,P < 0.001)。作者的模型结合了CD3+细胞计数、HCT和PBV(L),在训练数据集中调整R 2为0.87,均方根误差为0.26,在测试数据集中对CD3+细胞产量具有高度预测性。使用该算法估算PBV的在线应用程序可访问https://cd3yield.shinyapps.io/cd3yield/。

展开英文摘要原文

This retrospective review of 262 T-cell harvests, with a control cohort of healthy donors, analyzed the parameters impacting CD3+ T-cell yield in adults with B-cell malignancies. The overall aim was to design a novel predictive algorithm to guide the required processed blood volume (PBV) (L) on the apheresis machine to achieve a specific CD3+ target yield.

Factors associated with CD3+ T-cell yield on multivariate analysis included peripheral blood CD3+ count (natural log, 10 9 /L), hematocrit (HCT) and PBV with coefficients of 0.86 (95% confidence interval [CI], 0.80-0.92, P < 0.001), 1.30 (95% CI, 0.51-2.08, P = 0.001) and 0.09 (95% CI, 0.07-0.11, P < 0.001), respectively. The authors' model, incorporating CD3+ cell count, HCT and PBV (L), with an adjusted R 2 of 0.87 and root-mean-square error of 0.26 in the training dataset, was highly predictive of CD3+ cell yield in the testing dataset. An online application to estimate PBV using this algorithm can be accessed at https://cd3yield.shinyapps.io/cd3yield/.

The authors propose a transferrable model that incorporates clinical and laboratory variables accessible pre-harvest for use across the field of T-cell therapy. Pending further validation, such a model may be used to generate an individual leukapheresis plan and streamline the process of cell harvest, a well-recognized bottleneck in the industry.

论文信息

作者
O'Reilly MA、Malhi A、Cheok KPL、Ings S、Balsa C、Keane H、Jalowiec K、Neill L
单位
University College London Cancer Institute, London, UK; Department of Hematology, University College London Hospital, London, UK. Electronic address: maeve.o'reilly@ucl.ac.uk.United Kingdom
文献类型
非美国政府资助研究
期刊
Cytotherapy2023 Mar
原文标识
PubMed 36513573 · DOI 10.1016/j.jcyt.2022.10.012